RecruitingNCT06746883

A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection

A Single-arm, Open-label, Prospective, Observational Study to Assess the Safety of Sulbactam-durlobactam, Including the Risk of Hypersensitivity Reactions (Including Anaphylaxis) in Participants With Acinetobacter Baumannii-calcoaceticus Complex Infection


Sponsor

Innoviva Specialty Therapeutics

Enrollment

100 participants

Start Date

Apr 28, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this observational study is to evaluate the safety of sulbactam-durlobactam, as well as the risk of hypersensitivity reactions (including anaphylaxis) in participants with Acinetobacter baumannii-calcoaceticus complex infection. Participants will be followed for approximately 28 days in order to collect safety and reaction data.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Participant is ≥18 years old at the time of written informed consent and is hospitalized.
  • Participant has provided the written informed consent. If a participant is unable to provide written informed consent due to their medical condition, the participant's legally authorized representative may consent on behalf of the participant, or the decision can be made according to the procedure permitted by local law and institutional standard operating procedures (SOPs).
  • Participant has a proven or strongly suspected diagnosis of an infection caused by susceptible ABC isolates, based on investigator's clinical judgment.
  • Participant initiates treatment with SUL-DUR per routine clinical care. Participants who receive SUL-DUR within 24 hours prior to enrollment are also eligible to participate. The decision to treat the participant with SUL-DUR is made prior to and independently of study participation.
  • The participant has an expected survival of >48 hours at the time of written informed consent.

Exclusion Criteria1

  • A history of significant hypersensitivity or allergic reaction to any β-lactam, or any contraindication to the use of β-lactam antibiotics

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNon-interventional

Non-interventional


Locations(8)

University of Kansas Medical Center-Kansas City-3901 Rainbow Blvd

Kansas City, Kansas, United States

University of Kentucky College of Medicine

Lexington, Kentucky, United States

Ochsner Medical Center - New Orleans

New Orleans, Louisiana, United States

Ochsner LSU Health Science Center Shreveport

Shreveport, Louisiana, United States

Montefiore Medical Group Family Care Center

The Bronx, New York, United States

Summa Health System - Akron - 75 Arch Street

Akron, Ohio, United States

The Carl and Edyth Lindner Center for Research and Education at Christ Hospital

Cincinnati, Ohio, United States

Prisma Health - Infectious Diseases - Greenville

Greenville, South Carolina, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06746883


Related Trials